– Raises full-year 2026 LINZESS ® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year;...
Barchart Research What to Expect from IRWD Earnings IRWD Generated August 5, 2026 Current Price $4.15 EPS Estimate $$0.26 Consensus Rating Moderate Buy Average Move 13.35% Ironwood Pharmaceuticals Has...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6,...
– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4 th ...
– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS...
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory...
– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue...